U.S. Department of Energy

Pacific Northwest National Laboratory

Tom Metz

Professional Title: 
Scientist & Team Lead
Email: 
thomas.metz@pnnl.gov
Biography: 

Tom Metz is a Principal Investigator within the Integrative Omics group at PNNL and the Metabolomics Team Lead for a group of scientists that focuses on development and applications of high throughput metabolomics and lipidomics methods to various biological questions. He has worked to develop state-of-the-art, high throughput MS-based metabolomics and lipidomics capabilities that are comparable to the existing world-class MS-based proteomics capabilities at PNNL.

Current projects include:

  • The NIAID-funded Omics - Lethal Human Viruses: Proteomics, Metabolomics, and Lipidomics Core. Our core performs mass spectrometry-based omics analyses of cell and mouse models of viral infection, including influenza, West Nile, MERS, and Ebola viruses. Samples are generated at collaborating laboratories, chemically inactivated using the MPLEx protocol, and then shipped to our laboratory for analysis.
  • The NIDDK-funded Proteomics Laboratory for The Environmental Determinants of Diabetes in the Young program. In this project, we are performing blinded proteomics analyses of children enrolled in TEDDY who have developed autoimmunity, as well as those who have progressed to clinical type 1 diabetes. The goal of the project is to identify proteins in the blood that characterize the autoimmune reponse and that may be indicative of ongoing beta cell loss.
  • The Pacific Northwest Advanced Compound Identification Core (PNACIC), funded under the NIH Common Fund Metabolomics Program Phase II. In this project, we are coupling advanced ion mobility separations of metabolites with quantum chemistry- and machine learning-based computational methods for predicting metabolite experimental properties. Our goal is to develop an analytical paradigm that relies on in silico-derived reference libraries and metabolite identification based on matching multiple molecular properties for highest confidence in compound identification, together with estimates of false discovery.

The HIRN CBDS group. Photo taken nduring the 2016 HIRN Anual Investigator Meeting, Hyatt Regency Hotel, Bethesda, MD.